RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains a Sector Perform rating on Pacira BioSciences (NASDAQ:PCRX) and raises the price target from $14 to $15.
October 04, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Pacira BioSciences and increased the price target from $14 to $15, indicating a slightly positive outlook.
The increase in price target from $14 to $15 by RBC Capital suggests a slightly positive outlook for Pacira BioSciences. Maintaining the Sector Perform rating indicates that the stock is expected to perform in line with the market. The news is moderately important as it reflects analyst sentiment and could influence investor perception.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100